Loosli, TomTomLoosliMoore, Carolyn BoltonCarolyn BoltonMooreBuzaalirwa, LydiaLydiaBuzaalirwaByakwaga, HelenHelenByakwagaÇelikağ, IpekIpekÇelikağChimbetete, CleophasCleophasChimbeteteEbasone, Peter VanesPeter VanesEbasoneGiandhari, JenniferJenniferGiandhariHan, NuriNuriHanHuwa, JacquelineJacquelineHuwaKasozi, CharlesCharlesKasoziMafoua, AdolpheAdolpheMafouaMessou, EugèneEugèneMessouMinga, AlbertAlbertMingaMuula, GuyGuyMuulaMuyindike, WinnieWinnieMuyindikeNdala, Arcel Christ MassambaArcel Christ MassambaNdalaSauermann, MamathaMamathaSauermannSemeere, AggreyAggreySemeereSingh, LavanyaLavanyaSinghKouyos, Roger DRoger DKouyosLessells, RichardRichardLessellsEgger, MatthiasMatthiasEgger0000-0001-7462-51322025-07-152025-07-152025-05-20https://boris-portal.unibe.ch/handle/20.500.12422/211530Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.enHIVdolutegravirdrug resistancesub-Saharan Africaviremia600 - Technology::610 - Medicine & healtharticle10.48620/895284039192310.1093/cid/ciaf204